These studies have shown that metformin produces significant radiosensitization over time, attributed to various mechanisms, such as the re-oxygenation of the existing hypoxic tumor [15], activation of the adenosine-monophosphate-activated protein kinase (AMPK)/mammalian target of rapamycin (mTOR) pathway [16] and other microenvironmental considerations that are operative for the enhancement, particularly glucose concentration at the time of metformin administration [17]. This evidence concerns the gene MTOR and neoplasm.